The CCSS will invest $ 1.4 million in anti-inhibitor coagulant complex for 21 hemophilic patients who have developed neutralizing antibodies which interfere with clotting factors.
Hemophiliacs suffer from a disorder that causes internal bleeding in joints, muscles in upper and lower limbs, digestive system, urinary system and other areas of the body.
There are two types of hemophilia and in Costa Rica there are 180 patients with type A, and 32 patients with type B.